PriceTargets.com logo

Arsanis - ASNS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.33 As of 08/19/2022 01:00 AM ET
▼ -0.04 (-2.92%)
Get New Arsanis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASNS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Arsanis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.33.

This chart shows the closing price for ASNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Arsanis. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/13/2018Piper Jaffray CompaniesLower TargetNeutral$2.50High
7/9/2018CitigroupDowngradeBuy ➝ NeutralLow
7/2/2018CowenDowngradeOutperform ➝ Market PerformHigh
6/28/2018Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
6/28/2018Cantor FitzgeraldReiterated RatingBuy$26.00High
5/10/2018Cantor FitzgeraldSet TargetBuy$26.00Medium
3/15/2018Cantor FitzgeraldSet TargetBuy$26.00High
3/9/2018Cantor FitzgeraldSet TargetBuy$26.00Low
2/14/2018Cantor FitzgeraldInitiated CoverageOverweight$26.00Medium
12/11/2017CitigroupInitiated CoverageBuy ➝ Buy$27.00High
12/11/2017CowenInitiated CoverageOutperformHigh
12/11/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$23.00High
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Arsanis logo
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $1.33
Low: $1.30
High: $1.37

50 Day Range

MA: $3.11
Low: $3.11
High: $3.11

52 Week Range

Now: $1.33
Low: $1.15
High: $28.69

Volume

47,690 shs

Average Volume

130,074 shs

Market Capitalization

$23.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Arsanis?

The following Wall Street analysts have issued reports on Arsanis in the last twelve months:
View the latest analyst ratings for ASNS.

What is the current price target for Arsanis?

0 Wall Street analysts have set twelve-month price targets for Arsanis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Arsanis in the next year.
View the latest price targets for ASNS.

What is the current consensus analyst rating for Arsanis?

Arsanis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ASNS.

What other companies compete with Arsanis?

Other companies that are similar to Arsanis include Vislink Technologies, UTStarcom, COMSovereign, Rekor Systems and WidePoint. Learn More about companies similar to Arsanis.

How do I contact Arsanis' investor relations team?

Arsanis' physical mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company's listed phone number is (857) 529-8300 and its investor relations email address is [email protected] The official website for Arsanis is www.arsanis.com. Learn More about contacing Arsanis investor relations.